相似文献
1
Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?控制饮食中的胆固醇摄入对于改善非酒精性脂肪肝疾病是否足够有效？
World J Gastroenterol. 2010 Feb 21;16(7):800-3. doi: 10.3748/wjg.v16.i7.800.
2
NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.NPC1L1 抑制剂依折麦布是一种可靠的治疗药物，可用于非肥胖的非酒精性脂肪性肝病患者。
Lipids Health Dis. 2010 Mar 12;9:29. doi: 10.1186/1476-511X-9-29.
3
Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment.NPC1L1 在肝脏代谢调节中的新作用：依折麦布在 NAFLD/NASH 治疗中的潜在作用。
Curr Vasc Pharmacol. 2011 Jan;9(1):121-3. doi: 10.2174/157016111793744715.
4
Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?依泽替米贝作为非酒精性脂肪性肝病的一种潜在治疗方法：肠道是调节肝胰岛素敏感性和肝脂肪堆积的因素吗？
Drug Discov Today. 2010 Aug;15(15-16):590-5. doi: 10.1016/j.drudis.2010.06.007. Epub 2010 Jun 18.
5
Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.依折麦布可改善高脂高胆固醇饮食诱导的小鼠非酒精性脂肪性肝病。
Eur J Pharmacol. 2008 Apr 14;584(1):118-24. doi: 10.1016/j.ejphar.2008.01.045. Epub 2008 Feb 12.
6
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.长期依折麦布治疗非酒精性脂肪性肝病患者的疗效。
J Gastroenterol. 2011 Jan;46(1):101-7. doi: 10.1007/s00535-010-0291-8. Epub 2010 Jul 24.
7
[The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD)].依折麦布对非酒精性脂肪性肝病（NAFLD）的疗效
Nihon Shokakibyo Gakkai Zasshi. 2011 Aug;108(8):1383-92.
8
The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.尼曼-匹克 C1 样蛋白 1（NPC1L1）抑制剂依折麦布通过降低肥胖雄性小鼠肝脏中的肝 X 受体（LXR）活性改善代谢疾病。
Endocrinology. 2014 Aug;155(8):2810-9. doi: 10.1210/en.2013-2143. Epub 2014 Apr 28.
9
Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.依折麦布可改善代谢综合征肥胖大鼠模型中的肝脏脂肪变性和胰岛素抵抗。
FEBS Lett. 2007 Dec 11;581(29):5664-70. doi: 10.1016/j.febslet.2007.11.023. Epub 2007 Nov 20.
10
Ezetimbe as potential treatment for cholesterol gallstones: the need for clinical trials.依泽替米贝作为胆固醇性胆囊结石治疗药物的潜力：临床试验的必要性。
World J Gastroenterol. 2010 Apr 7;16(13):1555-7. doi: 10.3748/wjg.v16.i13.1555.
引用本文的文献
1
Coronary Microvascular Dysfunction is Associated with Augmented Lysosomal Signaling in Hypercholesterolemic Mice.冠状动脉微血管功能障碍与高胆固醇血症小鼠溶酶体信号增强有关。
bioRxiv. 2024 Jul 12:2024.07.10.603000. doi: 10.1101/2024.07.10.603000.
2
Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease.代谢相关脂肪性肝病表型中血脂和脂蛋白谱与肝脂肪含量的变化关系。
Front Endocrinol (Lausanne). 2021 Nov 26;12:691556. doi: 10.3389/fendo.2021.691556. eCollection 2021.
3
Egg and cholesterol consumption and mortality from cardiovascular and different causes in the United States: A population-based cohort study.鸡蛋和胆固醇摄入与美国心血管疾病和其他原因死亡率的关系：一项基于人群的队列研究。
PLoS Med. 2021 Feb 9;18(2):e1003508. doi: 10.1371/journal.pmed.1003508. eCollection 2021 Feb.
4
Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease.遗传和代谢构成中的种族差异与异质性对非酒精性脂肪性肝病的影响。
Diabetes Metab Syndr Obes. 2019 Mar 19;12:357-367. doi: 10.2147/DMSO.S182331. eCollection 2019.
5
Egg consumption and risk of non-alcoholic fatty liver disease.鸡蛋消费与非酒精性脂肪性肝病风险
World J Hepatol. 2017 Apr 8;9(10):503-509. doi: 10.4254/wjh.v9.i10.503.
6
A Grape Seed Procyanidin Extract Ameliorates Fructose-Induced Hypertriglyceridemia in Rats via Enhanced Fecal Bile Acid and Cholesterol Excretion and Inhibition of Hepatic Lipogenesis.葡萄籽原花青素提取物通过增强粪便胆汁酸和胆固醇排泄以及抑制肝脏脂肪生成来改善果糖诱导的大鼠高甘油三酯血症。
PLoS One. 2015 Oct 12;10(10):e0140267. doi: 10.1371/journal.pone.0140267. eCollection 2015.
7
Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.非酒精性脂肪性肝病相关肝细胞癌的临床特征：一项人体研究综述
Clin J Gastroenterol. 2015 Feb;8(1):1-9. doi: 10.1007/s12328-014-0548-5. Epub 2015 Jan 10.
8
The influence of dietary fat on liver fat accumulation.膳食脂肪对肝脏脂肪堆积的影响。
Nutrients. 2014 Nov 10;6(11):5018-33. doi: 10.3390/nu6115018.
9
Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.非酒精性脂肪性肝病的管理：一项基于证据的临床实践综述
World J Gastroenterol. 2014 Sep 14;20(34):12182-201. doi: 10.3748/wjg.v20.i34.12182.
10
Effect of diet on expression of genes involved in lipid metabolism, oxidative stress, and inflammation in mouse liver-insights into mechanisms of hepatic steatosis.饮食对小鼠肝脏中参与脂质代谢、氧化应激和炎症的基因表达的影响——对肝脂肪变性机制的深入了解
PLoS One. 2014 Feb 14;9(2):e88584. doi: 10.1371/journal.pone.0088584. eCollection 2014.
本文引用的文献
1
Analysis of transcriptome and metabolome profiles alterations in fatty liver induced by high-fat diet in rat.高脂饮食诱导大鼠脂肪肝中转录组和代谢组谱改变的分析。
Metabolism. 2010 Apr;59(4):554-60. doi: 10.1016/j.metabol.2009.08.022. Epub 2009 Nov 14.
2
n-3 PUFA and lipotoxicity.n-3多不饱和脂肪酸与脂毒性
Biochim Biophys Acta. 2010 Mar;1801(3):362-6. doi: 10.1016/j.bbalip.2009.09.010. Epub 2009 Sep 23.
3
The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression.原发性胆汁性肝硬化患者肝脏胆固醇代谢状态：MDR3 表达的作用。
Hepatol Int. 2009 Sep;3(3):490-6. doi: 10.1007/s12072-009-9137-y. Epub 2009 Jun 16.
4
A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.一项使用辛伐他汀治疗非酒精性脂肪性肝炎的初步研究：一项随机安慰剂对照试验。
J Clin Gastroenterol. 2009 Nov-Dec;43(10):990-4. doi: 10.1097/MCG.0b013e31819c392e.
5
Suppression of hepatic fat accumulation by highly purified eicosapentaenoic acid prevents the progression of d-galactosamine-induced hepatitis in mice fed with a high-fat/high-sucrose diet.高纯度二十碳五烯酸抑制肝脏脂肪堆积可预防高脂/高糖饮食喂养小鼠中d-半乳糖胺诱导的肝炎进展。
Biochim Biophys Acta. 2009 Apr;1791(4):281-8. doi: 10.1016/j.bbalip.2009.01.014. Epub 2009 Jan 31.
6
Recent advances in nonalcoholic fatty liver disease.非酒精性脂肪性肝病的最新进展
Curr Opin Gastroenterol. 2009 May;25(3):230-7. doi: 10.1097/mog.0b013e3283294a18.
7
Impact of cholesterol metabolism and the LXRalpha-SREBP-1c pathway on nonalcoholic fatty liver disease.胆固醇代谢及肝X受体α-固醇调节元件结合蛋白-1c通路对非酒精性脂肪性肝病的影响
Int J Mol Med. 2009 May;23(5):603-8. doi: 10.3892/ijmm_00000170.
8
Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol.非肥胖型非酒精性脂肪性肝病患者的营养调查：膳食胆固醇的意义
Scand J Gastroenterol. 2009;44(4):471-7. doi: 10.1080/00365520802588133.
9
Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.阿托伐他汀治疗非酒精性脂肪性肝炎伴血脂异常的疗效。
Metabolism. 2008 Dec;57(12):1711-8. doi: 10.1016/j.metabol.2008.07.030.
10
Current and emerging therapies in nonalcoholic fatty liver disease.非酒精性脂肪性肝病的现有及新兴疗法
Semin Liver Dis. 2008 Nov;28(4):396-406. doi: 10.1055/s-0028-1091984. Epub 2008 Oct 27.
Zotero 插件